IP Verse

Methods For Treating Progressive Multiple Sclerosis

Patent No. EP3095463 (titled "Methods For Treating Progressive Multiple Sclerosis") was filed by F Hoffmann LA Roche on Sep 16, 2009. The application was issued on Sep 9, 2020.

Patent Summary

Ocrelizumab dosing regimen for progressive multiple sclerosis that uses two initial doses to maximize B-cell depletion. The first exposure splits 0.6 grams into two 0.3-gram doses given 14 days apart, followed by a second 0.6-gram dose 24 weeks later. This approach targets CD20-positive B cells more effectively than single-dose regimens, reducing relapse rates and preventing disability progression in patients under 55 with active disease.

Patent Family

Patent family tree
Statuses, jurisdictions and citation links are shared on request.

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
BREUERJun 9, 2021BREUER
BREUERJun 9, 2021HOFFMANN EITLE
POLPHARMA BIOLOGICSJun 8, 2021WICHMANN

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

EP3095463

F HOFFMANN LA ROCHE
Application Number
EP16151683A
Filing Date
Sep 16, 2009
Status
Granted And Under Opposition
Aug 7, 2020
Publication Date
Sep 9, 2020
External Links
Slate, Register , Google Patents